We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVS Health (CVS) Reports Q4 Earnings: What Key Metrics Have to Say
Read MoreHide Full Article
For the quarter ended December 2022, CVS Health (CVS - Free Report) reported revenue of $83.85 billion, up 9.5% over the same period last year. EPS came in at $1.99, compared to $1.98 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $74.97 billion, representing a surprise of +11.84%. The company delivered an EPS surprise of +3.65%, with the consensus EPS estimate being $1.92.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how CVS Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Medical benefit ratio (MBR): 86% compared to the 84.83% average estimate based on five analysts.
Medical membership- Total: 24396 thousand compared to the 24282.42 thousand average estimate based on three analysts.
Adjusted Mail Choice Processed: 82.5 million compared to the 84.73 million average estimate based on three analysts.
Adjusted Claims Processed-Total: 600.4 million versus 585.76 million estimated by three analysts on average.
Revenue-Health Care Benefits: $23.03 billion versus the three-analyst average estimate of $21.83 billion. The reported number represents a year-over-year change of +11.3%.
Revenues-Products: $59.66 billion versus $51.86 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.5% change.
Revenues-Premiums: $21.44 billion compared to the $19.95 billion average estimate based on three analysts. The reported number represents a change of +11.6% year over year.
Revenue-Eliminations: -$11.27 billion versus the three-analyst average estimate of -$11.06 billion.
Net revenue-Pharmacy service segment: $43.75 billion versus $38.99 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +11.2% change.
Revenue-Retail/LTC segment: $28.18 billion compared to the $24.79 billion average estimate based on three analysts. The reported number represents a change of +4% year over year.
Revenues-Services: $2.43 billion versus $2.52 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -20.6% change.
Shares of CVS Health have returned -5.2% over the past month versus the Zacks S&P 500 composite's +7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CVS Health (CVS) Reports Q4 Earnings: What Key Metrics Have to Say
For the quarter ended December 2022, CVS Health (CVS - Free Report) reported revenue of $83.85 billion, up 9.5% over the same period last year. EPS came in at $1.99, compared to $1.98 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $74.97 billion, representing a surprise of +11.84%. The company delivered an EPS surprise of +3.65%, with the consensus EPS estimate being $1.92.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how CVS Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
View all Key Company Metrics for CVS Health here>>>
Shares of CVS Health have returned -5.2% over the past month versus the Zacks S&P 500 composite's +7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.